Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News German watchdog criticises EMA adaptive pathways approval Cost effectiveness agency critical of real world evidence plans
Views & Analysis The EMA’s Adaptive Pathways: are safety concerns exaggerated... Companies still need to provide a compelling case for efficacy
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
